MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma Total Liabilities 2011-2026 | ALBO
Annual Total Liabilities Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 126 M | 104 M | 71.9 M | 62.8 M | 7.97 M | 2.43 M | 1.87 M | 2.63 M | 8.59 M | 10.1 M | 4.43 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 126 M | 1.87 M | 36.7 M |
Quarterly Total Liabilities Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 221 M | 115 M | 113 M | 126 M | 115 M | 106 M | 102 M | 104 M | 104 M | 104 M | 104 M | 71.9 M | 71.9 M | 71.9 M | 71.9 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 7.97 M | 7.97 M | 7.97 M | 7.97 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 15.2 M | 1.87 M | 1.87 M | 1.46 M | 2.16 M | 2.63 M | 2.63 M | 2.63 M | 6.57 M | 8.59 M | 8.59 M | 8.59 M | 9.39 M | 10.1 M | 10.1 M | 10.1 M | 4.64 M | 4.43 M | 4.43 M | 4.43 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 221 M | 1.46 M | 43.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
Adagene
ADAG
|
38.7 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.71 | 1.88 % | $ 17 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
845 M | $ 25.87 | -0.79 % | $ 1.25 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
25.4 M | $ 2.97 | 3.12 % | $ 908 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 215.29 | 4.59 % | $ 5 B |  Danmark |
 |
BioNTech SE
BNTX
|
3.12 B | $ 105.97 | -2.78 % | $ 27.2 B | Germany |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Bio-Path Holdings
BPTH
|
2.78 M | - | - | $ 100 K | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
34.3 M | - | 0.59 % | $ 63 K | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
106 M | $ 64.74 | 1.41 % | $ 8.66 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 9.63 | -0.93 % | $ 1.56 B | Britain |
 |
CASI Pharmaceuticals
CASI
|
30.3 M | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Celldex Therapeutics
CLDX
|
45.3 M | $ 25.15 | -1.95 % | $ 1.62 M | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 14.01 | 3.7 % | $ 922 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
11.3 B | $ 164.87 | 0.27 % | $ 24 B | USA |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
BioVie
BIVI
|
2.55 M | $ 1.23 | 2.07 % | $ 1.82 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
124 M | $ 23.32 | 2.71 % | $ 2.76 B | USA |
 |
Calithera Biosciences
CALA
|
15.7 M | - | -10.95 % | $ 876 K | USA |